Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743598 · ClinicalTrials.gov registry record · Phase 4
Liraglutide for HIV-associated Neurocognitive Disorder
A Phase 4 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02743598: Clinical Trial Phase 4 study, sponsored by Temple University.
NCT02743598 is a Phase 4 study that was terminated before completion, run by Temple University. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02743598, a Phase 4 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
Interventions
- DRUG Liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-09 |
| Phase | Phase 4 |
Why NCT02743598 stopped before completion
NCT02743598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Liraglutide is the first listed.
NCT02743598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02743598 about?
NCT02743598 is a clinical study titled "Liraglutide for HIV-associated Neurocognitive Disorder". This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
What is the current status of trial NCT02743598?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2016-09. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02743598?
The interventions under investigation include: Liraglutide (DRUG).
Who is sponsoring clinical trial NCT02743598?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02743598's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia